This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)

Tipranks - Tipranks - Fri Jun 19, 7:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT) with bullish sentiments.

Claim 55% Off TipRanks

Odyssey Therapeutics, Inc. (ODTX)

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Odyssey Therapeutics, Inc., with a price target of $40.00. The company’s shares closed last Wednesday at $18.48.

According to TipRanks.com, Jones is a 5-star analyst with an average return of 16.3% and a 41.2% success rate. Jones covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Acrivon Therapeutics, Inc., and ArriVent BioPharma, Inc. ;'>

Currently, the analyst consensus on Odyssey Therapeutics, Inc. is a Strong Buy with an average price target of $28.24, implying a 56.0% upside from current levels. In a report issued on June 16, Wedbush also maintained a Buy rating on the stock with a $30.00 price target.

See the top stocks recommended by analysts >>

Capricor Therapeutics (CAPR)

Oppenheimer analyst Leland Gershell reiterated a Buy rating on Capricor Therapeutics today and set a price target of $54.00. The company’s shares closed last Wednesday at $27.95.

According to TipRanks.com, Gershell is a 4-star analyst with an average return of 6.9% and a 39.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Lexeo Therapeutics, Inc., and Protara Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capricor Therapeutics with a $53.29 average price target.

Medtronic (MDT)

In a report issued on June 15, Larry Biegelsen from Wells Fargo maintained a Buy rating on Medtronic, with a price target of $102.00. The company’s shares closed last Wednesday at $78.14, close to its 52-week low of $75.96.

According to TipRanks.com, Biegelsen is a 3-star analyst with an average return of 1.0% and a 48.3% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $97.90, representing a 20.9% upside. In a report issued on June 4, BTIG also upgraded the stock to Buy with a $90.00 price target.

Read More on ODTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).